SAN ANTONIO (EGMN) - Adjuvant exemestane appears to have little effect on cognitive function in postmenopausal women with breast cancer, but women on adjuvant tamoxifen perform significantly worse than healthy controls in several cognitive domains after 1 year of treatment, based on results of a substudy of the TEAM (Tamoxifen Exemestane Adjuvant Multicenter) trial.After 1 year, there were no significant differences in cognition between women who received adjuvant exemestane (Aromasin) and healthy...